New Consortium unites charity, academic and private sectors in search for new treatments for dementia by supporting research into novel targets for neurodegeneration
MRC Technology will provide Parkinson's UK with support in oversight and management of intellectual property, allowing Parkinson's UK to maximise patient benefits and return on investment from their funded research.
The collaboration will screen selective and potent potassium channel activators to develop novel therapeutic interventions in migraine. Drawing on MRC Technology’s commercialisation expertise in drug discovery, the project focuses on bringing to clinic more effective pain treatments arising from the work of Dr Cader’s group in identifying KCNK18, the first gene underlying typical migraine.
The relocation of the Centre for Therapeutics Discovery. MRC Technology's drug discovery unit, will start the next step in campus growth, and is expected to be completed by 2015.
MRC Technology and Boston University Collaborate to Develop anti-IL-16 Antibody for Treatment of Inflammatory Conditions
MRC Technology, a technology transfer organisation, announced today it is collaborating with Boston University to develop an anti-IL-16 antibody for use in treatment of inflammatory diseases and Ischaemic Reperfusion Injury (IRI).
MRC Technology and Renishaw Diagnostics Collaborate to Identify and Develop Infectious Disease Diagnostics
MRC Technology and Renishaw Diagnostics Collaborate to Identify and Develop Infectious Disease Diagnostics. Initiative combines expertise to accelerate clinical diagnostic screening
MRC Technology has successfully completed a project in collaboration with Bergen Teknologioverføring AS (BTO) where MRC Technology advised BTO on a licensing opportunity, providing recommendations for an optimal route forward.
The call aims to identify and fund projects focused on validation of potential small molecule or antibody targets in pathways important in the development or progression of musculoskeletal conditions. The call to UK-based academic researchers seeks to fund target validation and proof of concept studies prior to initiating a full scale drug discovery project.
MRC Technology and Parkinson’s UK launch joint ‘Call for Targets’ to slow, stop or reverse the progression of Parkinson’s
The call aims to identify and fund either one or two projects focused on potential small molecule or antibody targets. It is targeted at academic researchers and seeks to fund target validation and proof of concept studies prior to initiating a full scale drug discovery project.